The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 13, 2016

Filed:

Jan. 29, 2013
Applicant:

Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Xuhui District, Shanghai, CN;

Inventors:

Kuiling Ding, Shanghai, CN;

Xiaoming Wang, Shanghai, CN;

Zheng Wang, Shanghai, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07C 229/34 (2006.01); C07D 205/08 (2006.01); C07D 205/04 (2006.01); C07C 67/08 (2006.01); C07C 68/00 (2006.01); C07C 69/734 (2006.01); C07C 69/96 (2006.01); C07C 227/32 (2006.01); C07C 227/16 (2006.01); C07F 9/50 (2006.01); C07F 15/00 (2006.01); C07C 67/343 (2006.01); C07C 67/31 (2006.01); C07C 227/18 (2006.01); C07C 229/30 (2006.01);
U.S. Cl.
CPC ...
C07D 205/04 (2013.01); C07C 67/08 (2013.01); C07C 67/31 (2013.01); C07C 67/343 (2013.01); C07C 68/00 (2013.01); C07C 69/734 (2013.01); C07C 69/96 (2013.01); C07C 227/16 (2013.01); C07C 227/18 (2013.01); C07C 227/32 (2013.01); C07C 229/30 (2013.01); C07C 229/34 (2013.01); C07D 205/08 (2013.01); C07F 9/5045 (2013.01); C07F 15/0033 (2013.01); C07C 2101/16 (2013.01);
Abstract

A process for the production of ezetimibe and intermediates used in said process are disclosed. A kind of Morita-Baylis-Hillman adduct can be altered to chiral carboxylic acid derivatives of β-arylamino α-methylene with high activity and selectivity by means of ally lamination reaction, and the above carboxylic acid derivatives of β-arylamino α-methylene can be altered to the chiral intermediates of ezetimibe by means of simple conversion and further synthesized into the chiral drug ezetimibe. The synthesis route introduces chirality through the use of a chiral catalysis method, thereby avoiding the use of the chiral auxiliary oxazolidinone; and the route is economical and eco-friendly.


Find Patent Forward Citations

Loading…